YCBD Stock Risk & Deep Value Analysis
cbdMD Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About YCBD Stock
We analyzed cbdMD Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran YCBD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
YCBD Risk Analysis & Red Flags
What Could Go Wrong
The company is severely undercapitalized with a $10M market cap and is likely burning cash at an unsustainable rate. Without immediate and substantial new financing, which would likely be highly dilutive to existing shareholders, the company faces an imminent liquidity crisis, potential bankruptcy, or delisting, leading to a near-total loss for investors.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Market capitalization of $10M for a publicly traded company indicates extreme distress.
- ⚠
Persistent negative free cash flow with no clear path to profitability.
- ⚠
High likelihood of continued significant share dilution to sustain operations.
- ⚠
Highly competitive and commoditized market with limited product differentiation.
- ⚠
History of struggling financials and operational instability.
Upcoming Risk Events
- 📅
Failure to secure adequate financing leading to liquidity crisis or bankruptcy
- 📅
Further significant share dilution exceeding 25% of current outstanding shares
- 📅
Continued revenue decline and increasing cash burn
- 📅
Potential delisting from exchange due to low market cap or share price
When to Reconsider
- 🚪
Announcement of further significant share dilution (e.g., >25% of current shares outstanding).
- 🚪
Quarterly revenue declines over 10% for two consecutive quarters.
- 🚪
Cash balance falling below $1M or less than one quarter of operating expenses.
Unlock YCBD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does cbdMD Inc (YCBD) Do?
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
42
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids. It also provides veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.
Visit cbdMD Inc WebsiteInvestment Thesis
This is a highly speculative bet on a 'phoenix from the ashes' scenario for a severely distressed micro-cap company. The investment thesis hinges entirely on an improbable confluence of events: a significant, non-dilutive capital raise, a dramatic positive shift in US federal CBD regulation, and/or an unexpected acquisition by a larger entity seeking a distressed asset, leading to a turnaround from its current precarious state.
Is YCBD Stock Undervalued?
Unlock the full AI analysis for YCBD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
YCBD Price Targets & Strategy
12-Month Target
$1.00
Bull Case
$1.50
Bear Case
$0.20
Valuation Basis
Based on highly speculative investor interest assuming minimal dilution and flat revenue, implying a $12.4M market cap.
Entry Strategy
Extremely speculative. Consider a very small allocation only on significant volume spikes above $1.00 or near recent lows below $0.70, with strict risk management.
Exit Strategy
Take profit on 50% of position at $1.50 if reached. Consider full exit if stock breaks decisively below $0.50 (indicating further deterioration).
Portfolio Allocation
0.1% for aggressive risk tolerance (highly speculative allocation).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does YCBD Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
The company operates in a highly commoditized market with low barriers to entry. Its brand power is limited and under threat from larger, better-funded competitors, making any sustainable competitive advantage highly improbable without significant capital infusion and strategic pivot.
Moat Erosion Risks
- •Intense competition from numerous private and public CBD brands.
- •Commoditization of CBD products and pricing pressure.
- •Lack of capital for significant R&D, marketing, or IP development.
YCBD Competitive Moat Analysis
Sign up to see competitive advantages
YCBD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish, with minor speculative pockets. Predominantly negative due to ongoing financial distress and lack of positive news.
Institutional Sentiment
Negative, with very limited institutional coverage or holdings due to extreme small-cap status and high risk. No recent upgrades/downgrades.
Insider Activity (Form 4)
No significant recent insider buying or selling reported, which in itself can be a neutral to negative signal for a distressed company.
Options Flow
Limited options activity, reflecting low investor interest and liquidity for this micro-cap stock.
Earnings Intelligence
Next Earnings
Estimated late-April 2026
Surprise Probability
High (due to low expectations and high volatility, but a 'surprise' might simply mean less bad than anticipated).
Historical Earnings Pattern
Likely highly volatile stock price reactions to earnings, with significant swings based on any perceived news, positive or negative, regarding cash position or future funding.
Key Metrics to Watch
Competitive Position
Top Competitor
Charlotte's Web Holdings (CWBHF)
Market Share Trend
Losing or negligible, struggling to maintain relevance in a competitive market.
Valuation vs Peers
Trading at a severe discount to most peers on traditional metrics due to its distressed state and poor growth prospects, but also lacks the scale and market position of larger competitors.
Competitive Advantages
- •Brand recognition within a niche segment of the CBD market (albeit limited).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive YCBD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late-April 2026)
- •Crucial new financing announcement (equity raise or debt restructuring)
- •Major cost-cutting initiatives implementation and positive cash flow guidance
Medium-Term (6-18 months)
- •Significant US federal regulatory clarity on CBD products
- •Strategic partnership or acquisition interest (as a potential target)
- •Successful introduction of a novel, revenue-generating product line
Long-Term (18+ months)
- •Broader cannabis/CBD industry consolidation benefiting smaller players
- •Development of a truly differentiated, proprietary CBD delivery mechanism or formulation
- •Achieving sustained profitability and positive free cash flow
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for YCBD?
- ✓
Announcement of a definitive, non-dilutive financing round or a strategic acquisition offer.
- ✓
Sustained quarterly revenue growth above 15% paired with gross margin expansion.
- ✓
Clear path and execution towards positive operating cash flow.
Bull Case Analysis
See what could go right with Premium
Competing with YCBD
See how cbdMD Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
cbdMD Inc YCBD | — | 0.5 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for cbdMD Inc (YCBD)?
As of March 26, 2026, cbdMD Inc has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does cbdMD Inc use?
YCBD is the ticker symbol for cbdMD Inc. The company trades on the ASE.
What is the risk level for YCBD stock?
Our analysis rates cbdMD Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the YCBD DVR analysis updated?
Our AI-powered analysis of cbdMD Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 26, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for YCBD (cbdMD Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.